This report seeks to show that given the fundamental nature of regulatory driven changes to the OTC derivatives industry and also the high technology costs involved (“the lemons”); that the deployment of this technology spend should not be viewed solely in the context of sunk compliance costs, but in the context of investing for competitive technology advantage (“lemonade”).
It looks at the essential process and data flows in the post-Dodd Frank OTC derivatives trading function and identifies fourteen (14) opportunities for technology differentiation, along functional and data dimensions. The report explores the technology features that underlie these opportunities and the complexities they impose and briefly touches on some of the new technology showing up in the industry stack.
To obtain a courtesy download of the report please submit a request below.
A download link to the paper will be provided.